ESC 2024 - In OCEANIC-AF, the effects of the novel factor XIa inhibitor asundexian versus apixaban were evulated in patients with AF at high stroke risk. Manesh Patel discusses the study results.
Factor XIa inhibitor versus DOAC in patients with AF at high stroke risk
Share
Save
Restart
Resume
Share this program on:
Choose a format
Completing the pre-test is required to access this content.
Completing the pre-survey is required to view this content.
Ready to Claim Your Credits?
You have attempts to pass this post-test. Take your time and review carefully before submitting.
Good luck!
Details
Presenters
Overview
Educational information
This video was recorded during the ESC Congress 2024 in London, UK.
Faculty
Manesh Patel is a cardiologist at Duke Hospital in Durham, NC, US.
Disclaimer
This recording was developed under auspices of PACE-CME. Views expressed in the recording are those of the presenter and do not necessarily reflect the views of PACE-CME.
Read our summary of OCEANIC-AF
Release date: 2 September 2024
Recommended
Details
Presenters
Overview
ESC 2024 - In OCEANIC-AF, the effects of the novel factor XIa inhibitor asundexian versus apixaban were evulated in patients with AF at high stroke risk. Manesh Patel discusses the study results.
Educational information
This video was recorded during the ESC Congress 2024 in London, UK.
Faculty
Manesh Patel is a cardiologist at Duke Hospital in Durham, NC, US.
Disclaimer
This recording was developed under auspices of PACE-CME. Views expressed in the recording are those of the presenter and do not necessarily reflect the views of PACE-CME.
Read our summary of OCEANIC-AF
Release date: 2 September 2024
Title
Share on ReachMD
CloseProgram Chapters
Segment Chapters
Playlist:
Recommended
Register
We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?